George Hahn

Welcome to The Week from PropG Media, where we break down what mattered and what it all means.

I'm George Hahn, and it's Friday, June 5th.

Today, we get into the growing cost of the AI boom, why one pharmaceutical CEO believes medicine may be more transformative than AI, and why Scott is now rethinking his support for military action in Iran.

Let's get into it.

This week, Scott and Ed took ProfgMarkets on the road.

On Friday, they were in San Francisco, the global capital of AI optimism.

And Scott had a reality check ready.

And yet the IPOs are still coming.

SpaceX, OpenAI, and Anthropic are all set to go public this year at a combined valuation of roughly $4 trillion.

Scott's advice to anyone holding shares in any of those companies was loud and clear.

By Monday night, the conversation had shifted from Silicon Valley to Hollywood and from the company's building AI to the people AI is supposedly replacing.

According to McKinsey, AI could redistribute roughly $60 billion of annual revenue across film and television within five years of mass adoption.

So Scott and Ed put the question directly to Netflix co-CEO Ted Sarandos.

Are the industry's fears justified?

For Sarandos, AI is another tool.

For investors, it's still a bet.

And that's becoming a theme of this moment.

Technologies with enormous promise that still have to prove they can deliver.

Which brings us to healthcare.

Scott has been saying for a while that GLP-1 drugs may be more transformative than AI.